February 2027 biotech catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

35 verified catalyst event(s) dated in February 2027, each linked to its official source. Verified as of 2026-10-02.

Date	Event	Company	Drug	Official source & verification
2027-02-01 in 4mo ESTIMATED	READOUT Ribociclib (LEE011) Rollover Study for Continued Access Phase 2 · Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies	NVS NOVARTIS AG	LEE011	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi Phase 1/2 · Acute Myeloid Leukemia	ABBV AbbVie Inc.	Azacitidine, IMGN632, Venetoclax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVID Phase 1/2 · Gaucher Disease, Type 2	Prevail Therapeutics	LY3884961, Methylprednisolone, Sirolimus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizu Phase 3 · Seizures, Lennox Gastaut Syndrome	SK Life Science, Inc.	Carisbamate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02-01 in 4mo ESTIMATED	READOUT ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment Phase 1/2 · Pancreatic Cancer, PDAC	Amplia Therapeutics Limited	AMP945 ascending doses, AMP945 RP2D	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors Phase 1/2 · Triple Negative Breast Cancer, Breast Cancer	Day One Biopharmaceuticals, Inc.	Emi-Le	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic Phase 3 · Triple Negative Breast Cancer, PD-L1 Positive	GILD GILEAD SCIENCES, INC.	Sacituzumab Govitecan-hziy, Pembrolizuma	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Promising ROd-cone DYstrophy Gene therapY Phase 1/2 · Retinitis Pigmentosa	SparingVision	SPVN06	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT Phase 3 · Relapsing-remitting Multiple Sclerosis	Celltrion	CT-P53, US-Ocrevus, EU-Ocrevus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Ne Phase 4 · Hemophilia A	Octapharma	Nuwiq	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies A Phase 1/2 · Lung Cancer, Non-small Cell, Lung Cancer Metastatic	KRYS Krystal Biotech, Inc.	KB707, Pembrolizumab (KEYTRUDA®), Chemot	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 Phase 2 · Metastatic Castration-resistant Prostate Cancer (mCRPC)	MediLink Therapeutics (Suzhou) Co.	YL201 for Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in C Phase 2 · Glioma	LLY ELI LILLY & Co	Abemaciclib, Temozolomide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician' Phase 2 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma	GNLX GENELUX Corp	Olvimulogene nanivacirepvec, Platinum ch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Assess Molecular Changes in Adult Participants With Moderate to Sever Phase 2 · Hidradenitis Suppurativa, Atopic Dermatitis	ABBV AbbVie Inc.	Lutikizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors Phase 1/2 · Solid Tumor, Adult	DualityBio Inc.	DB-1419	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Phase 2 · Systemic Sclerosis (SSc)	ARGX ARGENX SE	Efgartigimod PH20 SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT B-FREE Chronic Babesiosis Study Phase 2 · Chronic Babesiosis	SXTP 60 DEGREES PHARMACEUTICALS,	Tafenoquine 100mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040 Phase 3 · Obesity, Overweight	LLY ELI LILLY & Co	Orforglipron	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoi Phase 3 · Cardiac Diseases	Trust Bio-sonics, Inc.	NH002 (Perflutren Lipid Microspheres) In	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vacc Phase 2 · Encephalitis	Bavarian Nordic	MVA-BN-WEV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type Phase 1/2 · Obesity, Diabetes Mellitus, Type 2	ARWR ARROWHEAD PHARMACEUTICALS, I	ARO-ALK7	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Pr Phase 3 · Non Squamous Non Small Cell Lung Cancer	Celltrion	CT-P51, EU-approved Keytruda	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Ar Phase 2 · Rheumatoid Arthritis	ABBV AbbVie Inc.	Lutikizumab, Ravagalimab, ABBV-8736, ABB	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera Phase 2 · Polycythemia Vera (PV)	IRON Disc Medicine, Inc.	DISC-3405	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause Phase 1/2 · Vasomotor Symptoms Associated With Menopause, Healthy Volunteers	ABCL AbCellera Biologics Inc.	ABCL635	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid R Phase 2 · Smoking	LLY ELI LILLY & Co	Brenipatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortic Phase 1/2 · Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC)	Sovargen	SVG103	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagen Phase 2 · Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)	CADL Candel Therapeutics, Inc.	aglatimagene besadenovec + valacyclovir,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Phase 2 · Tardive Dyskinesia	NBIX NEUROCRINE BIOSCIENCES INC	NBI-1065890	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Eval Phase 2 · Age Related Cataracts	Ocusun Ophthalmic Pharmaceutical (	0.4% ZOC2017217, Control	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Place Phase 2 · MASH - Metabolic Dysfunction-Associated Steatohepatitis	Rivus Pharmaceuticals, Inc.	HU6	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study Phase 2 · Neurotrophic Keratitis	TearSolutions, Inc.	Lacripep, Vehicle Ophthalmic Solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis Phase 2 · Primary Knee Osteoarthritis	ENLV Enlivex Ltd.	Allocetra	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change
2027-02 (month) in 4mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute T Phase 3 · Migraine	Kallyope Inc.	Elismetrep	ClinicalTrials.gov ↗ ✓ Source-checked 2026-10-02 Sponsor-projected date — can change